Development of a new prevention maintenance therapy for postmenopausal women.
In spring 1998, breast cancer prevention emerged from being a concept to being a reality. The National Surgical Adjuvant Breast and Bowel Project prevention trial showed that tamoxifen reduced breast cancer by 45% in high-risk women between the ages of 35 and 75. Additionally, an evaluation of 10,550 patients randomized to osteoporosis trials of placebo versus raloxifene demonstrated a 50% reduction in the incidence of breast cancer in woman taking raloxifene. For the future, a Study of Tamoxifen Against Raloxifene (STAR) is ongoing in high-risk postmenopausal women. This chapter describes the biological rationale for the current clinical advances.
Jordan
V C
VC
Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA.
D000328:Adult; D000368:Aged; D000818:Animals; D001943:Breast Neoplasms / Q000517:prevention & control*; D016889:Endometrial Neoplasms / Q000139:chemically induced; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use; D017698:Postmenopause; D020849:Raloxifene Hydrochloride; D051381:Rats; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*
D004965:Estrogen Antagonists; D010880:Piperidines; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride